[{"indications": "Indications\u00a0anal fissure (section 1.7.4); extravasation (section 10.3)Sublingual: prophylaxis and treatment of anginaBuccal: prophylaxis and treatment of angina;\r\nadjunct in unstable angina; acute and congestive heart failureInjection: control of hypertension and myocardial\r\nischaemia during and after cardiac surgery; induction of controlled\r\nhypotension during surgery; congestive heart failure; unstable anginaTransdermal: see under preparations below", "name": "GLYCERYL TRINITRATE Transdermal preparations", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.6 Nitrates, calcium-channel blockers, and other antianginal drugs", "2.6.1 Nitrates", "GLYCERYL TRINITRATE", "Transdermal preparations"], "cautions": "Cautions\u00a0hypothyroidism; malnutrition; hypothermia; recent history of myocardial infarction; heart failure due to obstruction; hypoxaemia or other ventilation and perfusion\r\nabnormalities; susceptibility to angle-closure\r\nglaucoma; metal-containing transdermal systems should\r\nbe removed before magnetic resonance imaging procedures, cardioversion,\r\nor diathermy; avoid abrupt withdrawal; monitor blood pressure and heart rate during intravenous infusion; tolerance (\n(From 2.6.1 Nitrates: British National Formulary)\nTolerance\u00a0Many patients on long-acting or transdermal nitrates rapidly develop tolerance (with reduced therapeutic effects). Reduction of blood-nitrate concentrations to low levels for 4 to 8 hours each day usually maintains effectiveness in such patients. If tolerance is suspected during the use of transdermal patches they should be left off for several consecutive hours in each 24 hours; in the case of modified-release tablets of isosorbide dinitrate (and conventional formulations of isosorbide mononitrate), the second of the two daily doses should be given after about 8 hours rather than after 12 hours. Conventional formulations of isosorbide mononitrate should not usually be given more than twice daily unless small doses are used; modified-release formulations of isosorbide mononitrate should only be given once daily, and used in this way do not produce tolerance.);  interactions: Appendix 1 (nitrates)", "side-effects": "Side-effects\u00a0postural hypotension, tachycardia (but paradoxical\r\nbradycardia also reported); throbbing headache, dizziness; less commonly nausea, vomiting, heartburn, flushing, syncope,\r\ntemporary hypoxaemia, rash, application site reactions with transdermal\r\npatches; very rarely angle-closure glaucomaInjection\u00a0Specific side-effects following injection\r\n(particularly if given too rapidly) include severe hypotension, diaphoresis,\r\napprehension, restlessness, muscle twitching, retrosternal discomfort,\r\npalpitation, abdominal pain; prolonged administration has been associated\r\nwith methaemoglobinaemia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2637.htm", "doses": ["Sublingually, 0.3\u20131\u00a0mg, repeated as required;\r\nsee also under preparations", "By buccal administration, see under\r\npreparation", "By intravenous infusion, 10\u2013200\u00a0micrograms/minute,\r\nadjusted according to response; max. 400\u00a0micrograms/minute; consult\r\nproduct literature for recommended starting doses specific to indication", "By transdermal application, see under\r\npreparations", "Name[Percutol\u00ae (Aspire)] Ointment, glyceryl trinitrate 2%, net price 60\u00a0g = \u00a359.65. \r\n    Label:\r\n    Counselling, see administration below Excipients  include wool fatDose\u00a0prophylaxis of angina, usual dose 1\u20132\u00a0inches of ointment\r\nmeasured on to Applirule\u00ae, and applied (usually\r\nto chest, arm, or thigh) without rubbing in and secured with surgical\r\ntape, every 3\u20134 hours as required; to determine dose, \u00bd\u00a0inch on first\r\nday then increased by \u00bd\u00a0inch/day until headache occurs, then reduced\r\nby \u00bd\u00a0inchNote\u00a0Approx. 800\u00a0micrograms/hour absorbed from\r\n1 inch of ointment"], "pregnancy": "Pregnancy\u00a0not known to be harmful"}, {"indications": "Indications\u00a0anal fissure (section 1.7.4); extravasation (section 10.3)Sublingual: prophylaxis and treatment of anginaBuccal: prophylaxis and treatment of angina;\r\nadjunct in unstable angina; acute and congestive heart failureInjection: control of hypertension and myocardial\r\nischaemia during and after cardiac surgery; induction of controlled\r\nhypotension during surgery; congestive heart failure; unstable anginaTransdermal: see under preparations below", "name": "GLYCERYL TRINITRATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.6 Nitrates, calcium-channel blockers, and other antianginal drugs", "2.6.1 Nitrates", "GLYCERYL TRINITRATE"], "cautions": "Cautions\u00a0hypothyroidism; malnutrition; hypothermia; recent history of myocardial infarction; heart failure due to obstruction; hypoxaemia or other ventilation and perfusion\r\nabnormalities; susceptibility to angle-closure\r\nglaucoma; metal-containing transdermal systems should\r\nbe removed before magnetic resonance imaging procedures, cardioversion,\r\nor diathermy; avoid abrupt withdrawal; monitor blood pressure and heart rate during intravenous infusion; tolerance (\n(From 2.6.1 Nitrates: British National Formulary)\nTolerance\u00a0Many patients on long-acting or transdermal nitrates rapidly develop tolerance (with reduced therapeutic effects). Reduction of blood-nitrate concentrations to low levels for 4 to 8 hours each day usually maintains effectiveness in such patients. If tolerance is suspected during the use of transdermal patches they should be left off for several consecutive hours in each 24 hours; in the case of modified-release tablets of isosorbide dinitrate (and conventional formulations of isosorbide mononitrate), the second of the two daily doses should be given after about 8 hours rather than after 12 hours. Conventional formulations of isosorbide mononitrate should not usually be given more than twice daily unless small doses are used; modified-release formulations of isosorbide mononitrate should only be given once daily, and used in this way do not produce tolerance.);  interactions: Appendix 1 (nitrates)", "side-effects": "Side-effects\u00a0postural hypotension, tachycardia (but paradoxical\r\nbradycardia also reported); throbbing headache, dizziness; less commonly nausea, vomiting, heartburn, flushing, syncope,\r\ntemporary hypoxaemia, rash, application site reactions with transdermal\r\npatches; very rarely angle-closure glaucomaInjection\u00a0Specific side-effects following injection\r\n(particularly if given too rapidly) include severe hypotension, diaphoresis,\r\napprehension, restlessness, muscle twitching, retrosternal discomfort,\r\npalpitation, abdominal pain; prolonged administration has been associated\r\nwith methaemoglobinaemia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2633.htm", "doses": ["Sublingually, 0.3\u20131\u00a0mg, repeated as required;\r\nsee also under preparations", "By buccal administration, see under\r\npreparation", "By intravenous infusion, 10\u2013200\u00a0micrograms/minute,\r\nadjusted according to response; max. 400\u00a0micrograms/minute; consult\r\nproduct literature for recommended starting doses specific to indication", "By transdermal application, see under\r\npreparations"], "pregnancy": "Pregnancy\u00a0not known to be harmful"}, {"indications": "Indications\u00a0anal fissure (section 1.7.4); extravasation (section 10.3)Sublingual: prophylaxis and treatment of anginaBuccal: prophylaxis and treatment of angina;\r\nadjunct in unstable angina; acute and congestive heart failureInjection: control of hypertension and myocardial\r\nischaemia during and after cardiac surgery; induction of controlled\r\nhypotension during surgery; congestive heart failure; unstable anginaTransdermal: see under preparations below", "name": "GLYCERYL TRINITRATE Short-acting tablets and sprays", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.6 Nitrates, calcium-channel blockers, and other antianginal drugs", "2.6.1 Nitrates", "GLYCERYL TRINITRATE", "Short-acting tablets and sprays"], "cautions": "Cautions\u00a0hypothyroidism; malnutrition; hypothermia; recent history of myocardial infarction; heart failure due to obstruction; hypoxaemia or other ventilation and perfusion\r\nabnormalities; susceptibility to angle-closure\r\nglaucoma; metal-containing transdermal systems should\r\nbe removed before magnetic resonance imaging procedures, cardioversion,\r\nor diathermy; avoid abrupt withdrawal; monitor blood pressure and heart rate during intravenous infusion; tolerance (\n(From 2.6.1 Nitrates: British National Formulary)\nTolerance\u00a0Many patients on long-acting or transdermal nitrates rapidly develop tolerance (with reduced therapeutic effects). Reduction of blood-nitrate concentrations to low levels for 4 to 8 hours each day usually maintains effectiveness in such patients. If tolerance is suspected during the use of transdermal patches they should be left off for several consecutive hours in each 24 hours; in the case of modified-release tablets of isosorbide dinitrate (and conventional formulations of isosorbide mononitrate), the second of the two daily doses should be given after about 8 hours rather than after 12 hours. Conventional formulations of isosorbide mononitrate should not usually be given more than twice daily unless small doses are used; modified-release formulations of isosorbide mononitrate should only be given once daily, and used in this way do not produce tolerance.);  interactions: Appendix 1 (nitrates)", "side-effects": "Side-effects\u00a0postural hypotension, tachycardia (but paradoxical\r\nbradycardia also reported); throbbing headache, dizziness; less commonly nausea, vomiting, heartburn, flushing, syncope,\r\ntemporary hypoxaemia, rash, application site reactions with transdermal\r\npatches; very rarely angle-closure glaucomaInjection\u00a0Specific side-effects following injection\r\n(particularly if given too rapidly) include severe hypotension, diaphoresis,\r\napprehension, restlessness, muscle twitching, retrosternal discomfort,\r\npalpitation, abdominal pain; prolonged administration has been associated\r\nwith methaemoglobinaemia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2622.htm", "doses": ["Sublingually, 0.3\u20131\u00a0mg, repeated as required;\r\nsee also under preparations", "By buccal administration, see under\r\npreparation", "By intravenous infusion, 10\u2013200\u00a0micrograms/minute,\r\nadjusted according to response; max. 400\u00a0micrograms/minute; consult\r\nproduct literature for recommended starting doses specific to indication", "By transdermal application, see under\r\npreparations", "Name[GTN 300 mcg (Martindale)] Sublingual tablets, glyceryl\r\ntrinitrate 300\u00a0micrograms, net price 100 =\r\n\u00a32.71. \r\n    Label:\r\n    16"], "pregnancy": "Pregnancy\u00a0not known to be harmful"}, {"indications": "Indications\u00a0anal fissure (section 1.7.4); extravasation (section 10.3)Sublingual: prophylaxis and treatment of anginaBuccal: prophylaxis and treatment of angina;\r\nadjunct in unstable angina; acute and congestive heart failureInjection: control of hypertension and myocardial\r\nischaemia during and after cardiac surgery; induction of controlled\r\nhypotension during surgery; congestive heart failure; unstable anginaTransdermal: see under preparations below", "name": "GLYCERYL TRINITRATE Longer-acting tablets", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.6 Nitrates, calcium-channel blockers, and other antianginal drugs", "2.6.1 Nitrates", "GLYCERYL TRINITRATE", "Longer-acting tablets"], "cautions": "Cautions\u00a0hypothyroidism; malnutrition; hypothermia; recent history of myocardial infarction; heart failure due to obstruction; hypoxaemia or other ventilation and perfusion\r\nabnormalities; susceptibility to angle-closure\r\nglaucoma; metal-containing transdermal systems should\r\nbe removed before magnetic resonance imaging procedures, cardioversion,\r\nor diathermy; avoid abrupt withdrawal; monitor blood pressure and heart rate during intravenous infusion; tolerance (\n(From 2.6.1 Nitrates: British National Formulary)\nTolerance\u00a0Many patients on long-acting or transdermal nitrates rapidly develop tolerance (with reduced therapeutic effects). Reduction of blood-nitrate concentrations to low levels for 4 to 8 hours each day usually maintains effectiveness in such patients. If tolerance is suspected during the use of transdermal patches they should be left off for several consecutive hours in each 24 hours; in the case of modified-release tablets of isosorbide dinitrate (and conventional formulations of isosorbide mononitrate), the second of the two daily doses should be given after about 8 hours rather than after 12 hours. Conventional formulations of isosorbide mononitrate should not usually be given more than twice daily unless small doses are used; modified-release formulations of isosorbide mononitrate should only be given once daily, and used in this way do not produce tolerance.);  interactions: Appendix 1 (nitrates)", "side-effects": "Side-effects\u00a0postural hypotension, tachycardia (but paradoxical\r\nbradycardia also reported); throbbing headache, dizziness; less commonly nausea, vomiting, heartburn, flushing, syncope,\r\ntemporary hypoxaemia, rash, application site reactions with transdermal\r\npatches; very rarely angle-closure glaucomaInjection\u00a0Specific side-effects following injection\r\n(particularly if given too rapidly) include severe hypotension, diaphoresis,\r\napprehension, restlessness, muscle twitching, retrosternal discomfort,\r\npalpitation, abdominal pain; prolonged administration has been associated\r\nwith methaemoglobinaemia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2626.htm", "doses": ["Sublingually, 0.3\u20131\u00a0mg, repeated as required;\r\nsee also under preparations", "By buccal administration, see under\r\npreparation", "By intravenous infusion, 10\u2013200\u00a0micrograms/minute,\r\nadjusted according to response; max. 400\u00a0micrograms/minute; consult\r\nproduct literature for recommended starting doses specific to indication", "By transdermal application, see under\r\npreparations", "Name[Suscard\u00ae (Forest)] Buccal tablets, m/r, glyceryl\r\ntrinitrate 2\u00a0mg, net price 100-tab pack = \u00a312.70; 3\u00a0mg,\r\n100-tab pack = \u00a318.33; 5\u00a0mg, 100-tab pack = \u00a324.96. Counselling, see\r\nbelowDose\u00a0treatment of angina, 2\u00a0mg as required, increased to 3\u00a0mg\r\nif necessary; prophylaxis 2\u20133\u00a0mg 3 times daily; 5\u00a0mg in severe anginaUnstable angina (adjunct), up to 5\u00a0mg with ECG monitoringCongestive heart failure, 5\u00a0mg 3 times daily, increased\r\nto 10\u00a0mg 3 times daily in severe casesAcute heart failure, 5\u00a0mg repeated until symptoms abateCounselling\u00a0Tablets have rapid onset of effect;\r\nthey are placed between upper lip and gum, and left to dissolve; vary\r\nsite to reduce risk of dental caries"], "pregnancy": "Pregnancy\u00a0not known to be harmful"}, {"indications": "Indications\u00a0anal fissure; angina, left ventricular failure\r\n(section 2.6.1); extravasation (section 10.3)", "name": "GLYCERYL TRINITRATE - MANAGEMENT OF ANAL FISSURES", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.7 Local preparations for anal and rectal disorders", "1.7.4 Management of anal fissures", "GLYCERYL TRINITRATE"], "cautions": "Cautions\u00a0section 2.6.1", "side-effects": "Side-effects\u00a0section 2.6.1; also diarrhoea, burning, itching,\r\nand rectal bleeding", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129349.htm", "doses": ["See preparations", "adult over 18 years, apply\r\n2.5\u00a0cm of ointment to anal canal every 12 hours until pain stops;\r\nmax. duration of use 8 weeks"], "pregnancy": "Pregnancy\u00a0section 2.6.1"}, {"indications": "Indications\u00a0anal fissure (section 1.7.4); extravasation (section 10.3)Sublingual: prophylaxis and treatment of anginaBuccal: prophylaxis and treatment of angina;\r\nadjunct in unstable angina; acute and congestive heart failureInjection: control of hypertension and myocardial\r\nischaemia during and after cardiac surgery; induction of controlled\r\nhypotension during surgery; congestive heart failure; unstable anginaTransdermal: see under preparations below", "name": "GLYCERYL TRINITRATE Parenteral preparations", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.6 Nitrates, calcium-channel blockers, and other antianginal drugs", "2.6.1 Nitrates", "GLYCERYL TRINITRATE", "Parenteral preparations"], "cautions": "Cautions\u00a0hypothyroidism; malnutrition; hypothermia; recent history of myocardial infarction; heart failure due to obstruction; hypoxaemia or other ventilation and perfusion\r\nabnormalities; susceptibility to angle-closure\r\nglaucoma; metal-containing transdermal systems should\r\nbe removed before magnetic resonance imaging procedures, cardioversion,\r\nor diathermy; avoid abrupt withdrawal; monitor blood pressure and heart rate during intravenous infusion; tolerance (\n(From 2.6.1 Nitrates: British National Formulary)\nTolerance\u00a0Many patients on long-acting or transdermal nitrates rapidly develop tolerance (with reduced therapeutic effects). Reduction of blood-nitrate concentrations to low levels for 4 to 8 hours each day usually maintains effectiveness in such patients. If tolerance is suspected during the use of transdermal patches they should be left off for several consecutive hours in each 24 hours; in the case of modified-release tablets of isosorbide dinitrate (and conventional formulations of isosorbide mononitrate), the second of the two daily doses should be given after about 8 hours rather than after 12 hours. Conventional formulations of isosorbide mononitrate should not usually be given more than twice daily unless small doses are used; modified-release formulations of isosorbide mononitrate should only be given once daily, and used in this way do not produce tolerance.);  interactions: Appendix 1 (nitrates)", "side-effects": "Side-effects\u00a0postural hypotension, tachycardia (but paradoxical\r\nbradycardia also reported); throbbing headache, dizziness; less commonly nausea, vomiting, heartburn, flushing, syncope,\r\ntemporary hypoxaemia, rash, application site reactions with transdermal\r\npatches; very rarely angle-closure glaucomaInjection\u00a0Specific side-effects following injection\r\n(particularly if given too rapidly) include severe hypotension, diaphoresis,\r\napprehension, restlessness, muscle twitching, retrosternal discomfort,\r\npalpitation, abdominal pain; prolonged administration has been associated\r\nwith methaemoglobinaemia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2631.htm", "doses": ["Sublingually, 0.3\u20131\u00a0mg, repeated as required;\r\nsee also under preparations", "By buccal administration, see under\r\npreparation", "By intravenous infusion, 10\u2013200\u00a0micrograms/minute,\r\nadjusted according to response; max. 400\u00a0micrograms/minute; consult\r\nproduct literature for recommended starting doses specific to indication", "By transdermal application, see under\r\npreparations", "Name[Nitronal\u00ae (Merck Serono) ] Injection, glyceryl trinitrate 1\u00a0mg/mL. To be diluted before use or given undiluted with syringe\r\npump. Net price 5-mL vial = \u00a31.80; 50-mL vial = \u00a314.76"], "pregnancy": "Pregnancy\u00a0not known to be harmful"}, {"indications": "Indications\u00a0anal fissure (section 1.7.4); extravasation (section 10.3)Sublingual: prophylaxis and treatment of anginaBuccal: prophylaxis and treatment of angina;\r\nadjunct in unstable angina; acute and congestive heart failureInjection: control of hypertension and myocardial\r\nischaemia during and after cardiac surgery; induction of controlled\r\nhypotension during surgery; congestive heart failure; unstable anginaTransdermal: see under preparations below", "name": "GLYCERYL TRINITRATE - NITRATES", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.6 Nitrates, calcium-channel blockers, and other antianginal drugs", "2.6.1 Nitrates", "GLYCERYL TRINITRATE"], "cautions": "Cautions\u00a0hypothyroidism; malnutrition; hypothermia; recent history of myocardial infarction; heart failure due to obstruction; hypoxaemia or other ventilation and perfusion\r\nabnormalities; susceptibility to angle-closure\r\nglaucoma; metal-containing transdermal systems should\r\nbe removed before magnetic resonance imaging procedures, cardioversion,\r\nor diathermy; avoid abrupt withdrawal; monitor blood pressure and heart rate during intravenous infusion; tolerance (\n(From 2.6.1 Nitrates: British National Formulary)\nTolerance\u00a0Many patients on long-acting or transdermal nitrates rapidly develop tolerance (with reduced therapeutic effects). Reduction of blood-nitrate concentrations to low levels for 4 to 8 hours each day usually maintains effectiveness in such patients. If tolerance is suspected during the use of transdermal patches they should be left off for several consecutive hours in each 24 hours; in the case of modified-release tablets of isosorbide dinitrate (and conventional formulations of isosorbide mononitrate), the second of the two daily doses should be given after about 8 hours rather than after 12 hours. Conventional formulations of isosorbide mononitrate should not usually be given more than twice daily unless small doses are used; modified-release formulations of isosorbide mononitrate should only be given once daily, and used in this way do not produce tolerance.);  interactions: Appendix 1 (nitrates)", "side-effects": "Side-effects\u00a0postural hypotension, tachycardia (but paradoxical\r\nbradycardia also reported); throbbing headache, dizziness; less commonly nausea, vomiting, heartburn, flushing, syncope,\r\ntemporary hypoxaemia, rash, application site reactions with transdermal\r\npatches; very rarely angle-closure glaucomaInjection\u00a0Specific side-effects following injection\r\n(particularly if given too rapidly) include severe hypotension, diaphoresis,\r\napprehension, restlessness, muscle twitching, retrosternal discomfort,\r\npalpitation, abdominal pain; prolonged administration has been associated\r\nwith methaemoglobinaemia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2633.htm", "doses": ["Sublingually, 0.3\u20131\u00a0mg, repeated as required;\r\nsee also under preparations", "By buccal administration, see under\r\npreparation", "By intravenous infusion, 10\u2013200\u00a0micrograms/minute,\r\nadjusted according to response; max. 400\u00a0micrograms/minute; consult\r\nproduct literature for recommended starting doses specific to indication", "By transdermal application, see under\r\npreparations"], "pregnancy": "Pregnancy\u00a0not known to be harmful"}]